Resources

Novel Coronavirus (COVID-19) Patient Tracking Report – Wave 3

As the novel coronavirus (COVID-19) pandemic continues to develop in the US, InCrowd wanted to understand how the experiences, perceptions, and predictions of patients who are immunocompromised or have chronic conditions have evolved over the course of this crisis.

We’d like to thank our friends at Rare Patient Voice for their help in sourcing this important research.

Methodology:

  • Method:
    • 10-Minute MicroSurvey via InCrowd
  • Crowds:
    • Patients with Mild to Severe Illnesses
  • Sample Size:
    • 152 Total Patients (Previous Waves: 159, 152)
      • 84 Mild to Moderate Patients (Previous Wave: 83, 77)
      • 68 Moderate to Severe Patients (Previous Wave: 76, 75)
  • Fielding Period:
    • October 7th – 8th

InCrowd’s other COVID-19 Tracking Reports:

Please fill out the form below to access this content

Name(Required)
This field is for validation purposes and should be left unchanged.

Related Resources

Instant Insights – Weight Loss Drugs

Instant Insights – Weight Loss Drugs

Prescriber Perspectives on Weight Loss Drugs in 2023 Examine how healthcare professionals (HCPs) view and prescribe weight loss drugs currently on the market in our new Instant Insights report. Fielded in a single day, this report includes responses from 100 qualified...

read more
Post-ASCO Excitement Report

Post-ASCO Excitement Report

Physician Perspectives on the 2023 ASCO Annual Meeting Curious what doctors thought about ASCO? Nearly 100 oncologists and hematologist oncologists shared with us the findings and developments they were most excited about. Check-out our 2023 Post-ASCO report to...

read more
2023 Q1 – NSCLC Essentials Readout

2023 Q1 – NSCLC Essentials Readout

Adoption of Newly-Approved 1L mNSCLC Regimens Driven by Promotional Activities Promotion plays a major role in the successful launch of a new pharmaceutical product. Companies must develop a marketing strategy that effectively communicates the benefits of the therapy...

read more